pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4745 |
Genomic Coordinates | chr19: 804940 - 805001 |
Description | Homo sapiens miR-4745 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4745-5p | |||||||||||||||||||||||||||||||||||||||||||||
Sequence | 2| UGAGUGGGGCUCCCGGGACGGCG |24 | |||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||||||||
Experiments | Illumina | DRVs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | PSMD11 | ||||||||||||||||||||
Synonyms | Rpn6, S9, p44.5 | ||||||||||||||||||||
Description | proteasome 26S subunit, non-ATPase 11 | ||||||||||||||||||||
Transcript | NM_002815 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on PSMD11 | |||||||||||||||||||||
3'UTR of PSMD11 (miRNA target sites are highlighted) |
>PSMD11|NM_002815|3'UTR 1 AGTTGGATCTGTAGCGGTCCTTTGGAGAGTGTGTGTGGCGGGAGAGTGAAACCTTGGGGGAAAATGCTAGGAGATTCTTT 81 TTTCTTTTTGTTCTACTTTTCGCTCGGAAAGTTTTTAAATCCTCATTTGGTGCATCTGTATTCCAGCCAATAGGTGTGCC 161 AGTTTTCATGTAATCTTTACTGGCCCAACTTGGGAGTGGGGAAATTGCTTAAAAAAAAAGAAAAAGAAAAAAAAAAAGAT 241 TATTCTAAATAAAAGGAAAAAGGCTTACACTACCTAAAGCTGTGCTCTCTGCCTCCTGGGAGAGGGCCGCAAAGCCAGGC 321 ACCCCGCCAACCACTGGGGGTCCTAATCCACCTGCTGGGCATCACCTCTCCTCCTCCTCAGAATTGGGTGTTTGCTGACC 401 ATCAAAAGCAATGACTTTTTATTCTGTTTGTACTGAACCAAAACAAACAACTGTGTATAGACTGCTGTTTTCTTTTTTAT 481 TTGAAATGAGGCATTTTGGTGTTCTTTCCCCTACCATACGGCCTGTCTGCCCTTCCCTCCCCACATTGGCTCCAGCAGAG 561 TAGCCGAAGGTCCTGCCGCCGCCGCCACCACCACCACCACTGCAGCAACAACAGCAGCAGCAGCAGCAGCGCCTGCATAG 641 CTCCACTCTGACCTGTGAAGGAATGGGGATGAGGCCAGGAGCTAGTGTCTACCACGGCCACACAGGGAGCAGTGTGGGCC 721 CTTAGCCCCCAAGGGGCCTGCTATGCATGTGGCTTTTTTTTTTTTTTTAAACACAGTAAACTAGATTAGTCGTCAGTGTT 801 TTAATTGCCCCTCTTCTCCTCTCCTGCATTCCTCTCCTCTCTTCTTTCCTCTCTGTCCCTTCTCTTTCCCCTCTCAACCA 881 GGAGACCATCATGTCTCTCTGCCTTCCTCCTCTCCCCTCCAGGGGAGTCAGGCTGTCTGTGAAAGCCATGAGCTTCTCTC 961 CCTCTCCCACTCCTCCTCTCCTACTTTCAGATGGATTTATTCCTTTTTTAAACAATGAACATCGGAAATGAGACTGTGGG 1041 GTGTGGTTTCTCTCTCTCTTTTTTTTTTAATTTTCTTTGTTGGGTTTTTGAGCAACCTCATGTCCCCTTCCCAGGGAGCT 1121 TTTTAATTTACCTCTTAGAACTCAAGTGGATGGGAAGTAGAGCACTATGTGTCAGTATGCTTTGTTTTCTGACACGATTA 1201 CACAGCGAGGCTTTAATGCCATTTGGGTAGGTGAGCTTCTGCACTTCTGTTGTGCTGAACTGTATTTTCTTCTCTCATCT 1281 CCTCTTTGTCTTTTTCTCTTTTCCTCTCCTTCCTGCCTTCTTCTGCTGGCCTCCTTTTCTCTTTCTTTACCTTCCTTGGA 1361 TTATCCTTCCAGGTTTTCATAATAAATTTATATTTTGTAAAAGGATTTTGTTGTACCAGGTTTTGCATCCTCACTGAATC 1441 TGACTGGCTTTTATTTTCCTCTCCAAAATCAGGTTTTTGTTCTCAACATCTTTCCCCATCATGTCTAGTCACTGTTTTGG 1521 TTTTGGCACCATCAGTATCAAATGTACAAACGGTTCTTGCTAACCAACACCAGGTATATCTGATGTTCAGATGAGTTCCA 1601 ATAAAAATAATTTTTTTTTTTTTCAAAAGGTGTCTTTTTCTTGAGTGCTGGAGGGCTTCCAAGCAAGTCCAGACAGCTCT 1681 GTGTGGCCCCACACTAGTCTAGCTCTCATCTGGCCAAAGCTGTTATCTCATTTGTGTAATGGGAGTCCTTAAGGTAAATT 1761 TGGGGTCCAAACTTGGAGGGCTTTGGGGGCAAGAAAGTTGGTGTGTGAGTTCTGAGGTTGGAAATGAGTTCAGGTGTCTT 1841 CTTCCAGGGCAGCATGGTCCAGTGAGCACATGTAAGTTTGGGCAGTAGATCCTCTGAGCCTACTTTCTCTTCTACTCAGT 1921 GAGGATGCTGCTTCCTTGGCAGGTGATTGTGATGTGAAGCTTAGTAAGTCATAGACGTGCAGGTGTCTGGAGAGTCCTGA 2001 CATGCAGTTGTGGTTTCGTTTCCTTTTGGAATCTTCAAAGGCAGCGATTTTCATATTGCCTCACACCCTGGCGGGGGCGG 2081 GGGGCTCTGGGACCACTGGGGGACCTGCTAAATCCTCTTCAGTCTGAGCAGTTCAGCCATTGTCAGTTTTAGTATTGTGT 2161 CTCTGTATTTCACTTGCAGAAAGAGCTTTGCTTCTATAAAGGACTTTAAAAAGTACTCCAAAGAGATCTAGTTTTGGAGT 2241 AGAGGGGAGATGTTTTCTCAAACTTAGGGCAGTCCTGAGATGCTCAGGCAGTAGCCCTTTTCTCAGTTCCCTTTGCGGGT 2321 CTTGGTCAGATGATGCCCTCTAGACCCGTGCTGTCCAATATGTAGCCGCTAGCCATGTGCAGCTGTCAGGCCCTTGCAAC 2401 GTGGCTGGTTCGAGCTGTGATACACTGCAAGTGTAAACACAAACCAGACTTCGAAGGCTTAGTATGATAACAAAAGAAAA 2481 GGAGTGTAAAATATGTCAATAACTTTTTTATATATGTGTTGAAATATTTTGGGTATTGGGTTAAATAAAATATATTATTA 2561 AAATTCAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | MCF7 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000261712.3 | 3UTR | CUCUCCCACUCCUCCUCUCCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000261712.3 | 3UTR | CUCUCCCACUCCUCCUCUCCU |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
85 hsa-miR-4745-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT100716 | TJAP1 | tight junction associated protein 1 | 2 | 2 | ||||||||
MIRT183592 | ZC3H11A | zinc finger CCCH-type containing 11A | 2 | 2 | ||||||||
MIRT338035 | DAZAP2 | DAZ associated protein 2 | 2 | 4 | ||||||||
MIRT395801 | SPCS3 | signal peptidase complex subunit 3 | 2 | 2 | ||||||||
MIRT443946 | LRIT3 | leucine rich repeat, Ig-like and transmembrane domains 3 | 2 | 2 | ||||||||
MIRT450579 | HIST1H2BG | histone cluster 1 H2B family member g | 2 | 6 | ||||||||
MIRT451616 | MEIS3P1 | Meis homeobox 3 pseudogene 1 | 2 | 2 | ||||||||
MIRT452330 | EIF5AL1 | eukaryotic translation initiation factor 5A-like 1 | 2 | 2 | ||||||||
MIRT453278 | EFTUD2 | elongation factor Tu GTP binding domain containing 2 | 2 | 2 | ||||||||
MIRT455213 | GNL1 | G protein nucleolar 1 (putative) | 2 | 2 | ||||||||
MIRT455469 | LYPLA2 | lysophospholipase II | 2 | 2 | ||||||||
MIRT456502 | PFKFB2 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | 2 | 2 | ||||||||
MIRT456686 | LDB1 | LIM domain binding 1 | 2 | 2 | ||||||||
MIRT456914 | DDA1 | DET1 and DDB1 associated 1 | 2 | 2 | ||||||||
MIRT457602 | IDS | iduronate 2-sulfatase | 2 | 2 | ||||||||
MIRT457849 | RNASEH2B | ribonuclease H2 subunit B | 2 | 4 | ||||||||
MIRT458454 | RPRM | reprimo, TP53 dependent G2 arrest mediator homolog | 2 | 2 | ||||||||
MIRT460178 | UNK | unkempt family zinc finger | 2 | 6 | ||||||||
MIRT461464 | SLC19A3 | solute carrier family 19 member 3 | 2 | 2 | ||||||||
MIRT464738 | UBE2Q1 | ubiquitin conjugating enzyme E2 Q1 | 2 | 2 | ||||||||
MIRT465278 | TRIM28 | tripartite motif containing 28 | 2 | 2 | ||||||||
MIRT468449 | SETD1B | SET domain containing 1B | 2 | 2 | ||||||||
MIRT468619 | SUMO1 | small ubiquitin-like modifier 1 | 2 | 6 | ||||||||
MIRT469151 | RNF121 | ring finger protein 121 | 2 | 2 | ||||||||
MIRT470072 | PTGES2 | prostaglandin E synthase 2 | 2 | 2 | ||||||||
MIRT470171 | PSMD11 | proteasome 26S subunit, non-ATPase 11 | 2 | 4 | ||||||||
MIRT473155 | MLLT1 | MLLT1, super elongation complex subunit | 2 | 2 | ||||||||
MIRT474307 | LAMC1 | laminin subunit gamma 1 | 2 | 2 | ||||||||
MIRT474781 | KIAA0895L | KIAA0895 like | 2 | 2 | ||||||||
MIRT476482 | GATAD2A | GATA zinc finger domain containing 2A | 2 | 2 | ||||||||
MIRT477612 | EFNA3 | ephrin A3 | 2 | 2 | ||||||||
MIRT479523 | CDCA4 | cell division cycle associated 4 | 2 | 2 | ||||||||
MIRT479972 | CARD10 | caspase recruitment domain family member 10 | 2 | 2 | ||||||||
MIRT480409 | C19orf47 | chromosome 19 open reading frame 47 | 2 | 2 | ||||||||
MIRT480425 | C17orf85 | nuclear cap binding subunit 3 | 2 | 2 | ||||||||
MIRT483571 | SYT2 | synaptotagmin 2 | 2 | 2 | ||||||||
MIRT483663 | QSOX2 | quiescin sulfhydryl oxidase 2 | 2 | 4 | ||||||||
MIRT484531 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT484614 | SIX3 | SIX homeobox 3 | 2 | 6 | ||||||||
MIRT485896 | ZFP36 | ZFP36 ring finger protein | 2 | 2 | ||||||||
MIRT486504 | MYH11 | myosin heavy chain 11 | 2 | 2 | ||||||||
MIRT487506 | GRK5 | G protein-coupled receptor kinase 5 | 2 | 2 | ||||||||
MIRT488851 | UBTF | upstream binding transcription factor, RNA polymerase I | 2 | 2 | ||||||||
MIRT489463 | MSC | musculin | 2 | 2 | ||||||||
MIRT491168 | LRP3 | LDL receptor related protein 3 | 2 | 2 | ||||||||
MIRT496626 | TMEM67 | transmembrane protein 67 | 2 | 2 | ||||||||
MIRT497615 | ANG | angiogenin | 2 | 2 | ||||||||
MIRT497765 | KIAA0895 | KIAA0895 | 2 | 2 | ||||||||
MIRT499679 | MRE11A | MRE11 homolog, double strand break repair nuclease | 2 | 6 | ||||||||
MIRT499772 | SLC29A2 | solute carrier family 29 member 2 | 2 | 2 | ||||||||
MIRT501744 | NSD1 | nuclear receptor binding SET domain protein 1 | 2 | 2 | ||||||||
MIRT504993 | ZNF652 | zinc finger protein 652 | 2 | 2 | ||||||||
MIRT511663 | HIST1H3C | histone cluster 1 H3 family member c | 2 | 2 | ||||||||
MIRT511689 | HIST1H2BO | histone cluster 1 H2B family member o | 2 | 4 | ||||||||
MIRT511702 | HIST1H2BL | histone cluster 1 H2B family member l | 2 | 4 | ||||||||
MIRT511733 | HIST1H2BE | histone cluster 1 H2B family member e | 2 | 8 | ||||||||
MIRT512857 | TBC1D13 | TBC1 domain family member 13 | 2 | 2 | ||||||||
MIRT513443 | EMP1 | epithelial membrane protein 1 | 2 | 6 | ||||||||
MIRT515680 | TFPI | tissue factor pathway inhibitor | 2 | 2 | ||||||||
MIRT523528 | GLUL | glutamate-ammonia ligase | 2 | 2 | ||||||||
MIRT525545 | PHB2 | prohibitin 2 | 2 | 4 | ||||||||
MIRT526208 | SNX24 | sorting nexin 24 | 2 | 2 | ||||||||
MIRT531555 | SRD5A1 | steroid 5 alpha-reductase 1 | 2 | 2 | ||||||||
MIRT533763 | TMEM135 | transmembrane protein 135 | 2 | 2 | ||||||||
MIRT545581 | SNRPA1 | small nuclear ribonucleoprotein polypeptide A' | 2 | 2 | ||||||||
MIRT552433 | ZNF460 | zinc finger protein 460 | 2 | 2 | ||||||||
MIRT561158 | BCL2L12 | BCL2 like 12 | 2 | 2 | ||||||||
MIRT562344 | EXOSC2 | exosome component 2 | 2 | 2 | ||||||||
MIRT570658 | KDM6B | lysine demethylase 6B | 2 | 2 | ||||||||
MIRT571075 | TCHHL1 | trichohyalin like 1 | 2 | 2 | ||||||||
MIRT571331 | TPCN2 | two pore segment channel 2 | 2 | 2 | ||||||||
MIRT571601 | TOB2 | transducer of ERBB2, 2 | 2 | 2 | ||||||||
MIRT573012 | RPP25 | ribonuclease P and MRP subunit p25 | 2 | 2 | ||||||||
MIRT609042 | EP300 | E1A binding protein p300 | 2 | 2 | ||||||||
MIRT613397 | DNAH17 | dynein axonemal heavy chain 17 | 2 | 2 | ||||||||
MIRT635588 | TTC9C | tetratricopeptide repeat domain 9C | 2 | 2 | ||||||||
MIRT644753 | TXNRD3NB | thioredoxin reductase 3 neighbor | 2 | 2 | ||||||||
MIRT661117 | FPR1 | formyl peptide receptor 1 | 2 | 2 | ||||||||
MIRT690102 | PNMA2 | paraneoplastic Ma antigen 2 | 2 | 2 | ||||||||
MIRT694971 | PLAC8 | placenta specific 8 | 2 | 2 | ||||||||
MIRT695514 | ALPI | alkaline phosphatase, intestinal | 2 | 2 | ||||||||
MIRT695576 | ASB16 | ankyrin repeat and SOCS box containing 16 | 2 | 2 | ||||||||
MIRT699569 | SIT1 | signaling threshold regulating transmembrane adaptor 1 | 2 | 2 | ||||||||
MIRT701990 | MIER3 | MIER family member 3 | 2 | 2 | ||||||||
MIRT725462 | GRAP2 | GRB2-related adaptor protein 2 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|